Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. - George DJ; Hessel C; Halabi S; Michaelson MD; Hahn O; Walsh M; Picus J; Small EJ; Dakhil S; Feldman DR; Mangeshkar M; Scheffold C; et al. (The oncologist, 2019)